OCULUX
The computed 12-month bankruptcy probability of OCULUX is 0.2% (very low). The 2024 annual accounts show equity of €150k. Its solvency ranks better than 21% of 381 sector peers (fiscal year 2024). The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €150k |
| Staff (FTE) | 6.1 |
| Better than sector | 21% |
| Active | 3 yrs |
Mixed profile: strong on stability, weaker on solvency.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 9.1% | 50.2% | |
| Equity | €150k | €128k | |
| Gross operating margin | €782k | €180k | |
| Staff costs | €506k | €135k | |
| Employees (FTE) | 6.1 | 2.2 |
| Fiscal year | 2024 |
|---|---|
| Revenue | - |
| EBITDA | €273k |
| Net profit | - |
| Cash flow | - |
| Staff costs | €506k |
| Income taxes | €2k |
| Dividends | - |
| Total assets | €1.66M |
| Equity | €150k |
| Debt | €1.51M |
| of which ≤ 1y | €1.05M |
| of which > 1y | €460k |
| Working capital | €-63k |
| Employees (FTE) | 6.1 |
| 2024 | |
|---|---|
| Current ratio | 0.94 |
| Quick ratio | 0.94 |
| Working capital ratio | -3.8% |
| Solvency | 9.1% |
| Debt / equity | 10.04 |
| Long-term debt ratio | 3.07 |
| Interest coverage | 5.26 |
| Gross margin | - |
| Net margin | - |
| ROA | - |
| ROE | - |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €1.66M |
| Fixed assets | 21/28 | €674k |
| Intangible fixed assets | 21 | €381k |
| Tangible fixed assets | 22/27 | €293k |
| Current assets | 29/58 | €983k |
| Amounts receivable within one year | 40/41 | €19k |
| Cash & bank | 54/58 | €899k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €1.66M |
| Equity | 10/15 | €150k |
| Contributions / capital | 10/11 | €150k |
| Amounts payable | 17/49 | €1.51M |
| Amounts payable after one year | 17 | €460k |
| Amounts payable within one year | 42/48 | €1.05M |
| Trade debts payable within one year | 44 | €19k |
| Income statement | ||
| Gross operating margin | 9900 | €782k |
| Operating result | 9901 | €54k |
| Financial income | 75 | €335 |
| Financial charges | 65 | €52k |
| Result before taxes | 9903 | €2k |
| Income taxes | 67/77 | €2k |
| NACE primary | Human health(86220) |
| Legal form | Private limited company(610) |
| Incorporation | 12-07-2023 |
| Status | Active |
| Postal code | 3960 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 72004B0411/00F000 | Flanders | 251 m² | 1 · 170 m² | 11.2 m · 2 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameNL | OCULUX |